NovaBiotics: NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia

NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting-diseases, announces that the Company's proprietary intravenous cysteamine bitartrate therapy candidate is included in a global Phase 3 clinical trial being conducted and funded as part of REMAP-CAP.